Company intelligence / Profile preview

Proof Diagnostics

Cambridge, Massachusetts, United Statesproofdiagnostics.com.ng ↗

Ownership: Private
Development stage: Preclinical

Overview

Proof Diagnostics developed scalable, sensitive, and cost-effective CRISPR-based diagnostic tests for infectious diseases, with an initial focus on COVID‑19. The company's technology enables rapid and reliable detection of viral RNA using gene-editing tools. It was acquired by Ginkgo Bioworks in early 2024.

Therapeutic areas: Infectious Diseases
Modalities: DeviceCRISPR-based diagnostic tool
Industry: Molecular Diagnostics

Partnerships

Ginkgo Bioworks

Beyond the preview

Go deeper on Proof Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proof Diagnostics.

Explore the full profile